Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05175547 · ClinicalTrials.gov registry record · Phase 3
Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke
A Phase 3 study, sponsored by ProMedica Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT05175547 is a Phase 3 study that has completed, run by ProMedica Health System. The registered enrollment target is 80 participants.
The verdict
NCT05175547, a Phase 3 study, has completed, sponsored by ProMedica Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.
Interventions
- DRUG Clevidipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-10-30 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05175547
The ClinicalTrials.gov registry entry for NCT05175547 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProMedica Health System, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clevidipine is the first listed.
NCT05175547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05175547 about?
NCT05175547 is a clinical study titled "Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke". The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.
What is the current status of trial NCT05175547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2021-10-30. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05175547?
The interventions under investigation include: Clevidipine (DRUG).
Who is sponsoring clinical trial NCT05175547?
This trial is sponsored by ProMedica Health System, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.